Abstract Details

Title Assessment and Follow-up of the Response to Disease Modifying Treatments in Multiple Sclerosis: Spanish Expert Consensus

Topic Multiple Sclerosis

Presentation(s) P9 - Poster Session 9 (12:00 PM-1:00 PM)

Poster/Presentation
Number 9-015

Objective The present study aims to establish recommendations agreed by Spanish multiple sclerosis (MS) experts on how, when and what variables should be measured to assess disease modifying treatments (DMTs) response.

Background MS presents great variability and heterogeneity, making its prognosis and treatment response uncertain. The establishment of unified therapeutic response criteria can optimize DMTs results.

Design/Methods 25 expert neurologists in MS were involved in the design of an online RAND/UCLA questionnaire (divided in 9 blocks and 54 questions) to obtain a national consensus in the evaluation of DMTs suboptimal response. Each block contained different number of questions and each question could be answered according to a 4-point Likert scale (strongly disagree, disagree, agree or strongly agree). Consensus was considered when the sum of the "Strongly Agree" and "Agree" or the sum of the "Strongly disagree" and "Disagree" responses was ≥66.6%.

Results 151 MS experts from 41 Spanish provinces, mostly working in tertiary hospitals (67.2%) participated in this national survey, of whom 64.9% (n=98) and 35.1% (n=53) of neurologists totally and partially completed the questionnaire, respectively. The proportion of agreement for each block was: 1) Therapeutic response: 77.8%, 2) Relapses: 100.0%, 3) Magnetic resonance imaging: 73.3%, 4) Biomarkers: 75.0%, 5) Disability progression: 100.0%, 6) Brain volume loss: 66.7%, 7) Neuropsychological aspects: 100.0%, 8) DMTs switch due to lack of response: 57.1%, 9) Clinical practice: 100.0%. The more challenging aspect to discuss was the DMTs switch due to lack of response; no agreement was obtained in this block of questions. Most of the experts (82.7%) state that the suggested practices are implementable in routine clinical practice.

Conclusions Consensus (≥66.6% agreement) was obtained in 8 out of the 9 blocks of the recommendations to assess DMTs response.

Authors/Disclosures
Jordi I. Rio, MD PRESENTER	The institution of Dr. Rio has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis, merck, sanofi, roche. The institution of Dr. Rio has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for novartis, merck, sanofi, roche. Dr. Rio has received personal compensation in the range of $0-$499 for serving as an Expert Witness for novartis, merck, sanofi, roche.
Joaquin Pena Martinez	Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cellgene. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Joaquin Pena Martinez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
Luis Brieva Ruiz, MD (Hospital Arnau Vilanova)	Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for All comercial companies interested in Multiple Sclerosis. Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Al comercial companies in Multiple Sclerosis. The institution of Dr. Brieva Ruiz has received research support from Carlos III Institut. Madrid. Spain..
Celia Oreja Guevara	Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for roche. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for merck. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for merck. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for roche. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for viatris. Celia Oreja Guevara has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for biogen. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for bms. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for jannsen.
	No disclosure on file
Alfredo Rodriguez Antiguedad, MD (Hospital Universitario Cruces Neurology Department)	Alfredo Rodriguez Antiguedad, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Alfredo Rodriguez Antiguedad, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Alfredo Rodriguez Antiguedad, MD has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for NOVARTIS. Alfredo Rodriguez Antiguedad, MD has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for BIOGEN. Alfredo Rodriguez Antiguedad, MD has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for MERCK.
Jose Manuel Garcia Dominguez (Hospital General Universitario Gregorio Marañón)	Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Johnson & Johnson. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Almirall. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb.
	No disclosure on file
MARIA JOSE MORENO JIMENEZ	No disclosure on file
Basilio Hernandez (GRIFOLS SA)	No disclosure on file
Rafael Arroyo Gonzalez	Rafael Arroyo Gonzalez has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details